医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HCL Technologies to Accelerate Digital Transformation at DSM

2022年07月18日 PM08:26
このエントリーをはてなブックマークに追加


 

NOIDA, India & HEERLEN, Netherlands

HCL Technologies (HCL), a leading global technology company, has signed a multi-year deal to drive the modernization of DSM’s core IT business systems and transition to a product-based IT operating model. HCL will help accelerate the digital transformation of DSM, a purpose-led science-based global leader in health, nutrition and bioscience, with a cloud-first strategy, agile delivery and next-generation security and network practice. By creating a seamlessly connected group-wide digital work environment, HCL will support DSM’s sustainable product innovation efforts and growth ambitions.

“To underpin DSM’s strategy and our purpose to improve the health of people and the planet, we are in the midst of a digital transformation so that we can better serve our customers,” said Ipek Ozsuer, DSM’s Chief Digital Officer. “We wanted to transition from a multi-vendor landscape and work with a sole integration partner that has the deep expertise to help drive our digital ambitions. HCL shares DSM’s values in placing sustainability at the heart of our digital roadmap, making them an ideal transformation partner.”

HCL’s Fenix 2.0 digital execution framework will drive best practices and accelerate transformation at scale across DSM’s business units and product lines. Through harnessing next-generation automation and analytics, HCL plans to enhance IT service delivery for approximately 18,000 end users across 200 sites in more than 50 countries.

“We’re delighted DSM chose HCL to support its digital transformation,” said Ashish Kumar Gupta, Chief Growth Officer, Europe and Africa, HCL Technologies. “DSM is a pioneer in responsible business and led by a purpose that is very much aligned with HCL’s own culture, values, and commitment supporting our global communities. This engagement is a testament to our successful track record in working closely with clients to support digital transformation across their business.”

For more information, visit www.hcltech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005425/en/

CONTACT

HCL Technologies

Meenakshi Benjwal, Americas

meenakshi.benjwal@hcl.com

Elka Ghudial, EMEA

elka.ghudial@hcl.com

Devneeta Pahuja, India and APAC

devneeta.p@hcl.com

 

同じカテゴリーの記事 

  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D
  • Takeda公布2023财年全年业绩和2024财年展望,确认对后期研发管线开发和提高核心营业利润率的承诺
  • Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系